PP
LUMO

PDT Partners’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

PDT Partners’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-38,887
Closed -$3.56M – 572
2017
Q3 		$3.56M Buy
38,887
+26,021
+202% +$2M 0.12% 214
2017
Q2 		$851K Buy
12,866
+7,922
+160% +$981K 0.03% 355
2017
Q1 		$1.07M Sell
4,944
-689
-12% -$98.4K 0.06% 316
2016
Q4 		$521K Sell
5,633
-3,078
-35% -$347K 0.03% 396
2016
Q3 		$1.18M Buy
+8,711
New +$865K 0.07% 288
2016
Q2 		– Sell
-9,114
Closed -$1.49M – 578
2016
Q1 		$1.49M Buy
9,114
+14
+0.2% +$2.84K 0.09% 266
2015
Q4 		$2.98M Buy
9,100
+5,322
+141% +$1.73M 0.41% 117
2015
Q3 		$1.22M Sell
3,778
-324
-8% -$142K 0.03% 659
2015
Q2 		$1.63M Buy
+4,102
New +$1.74M 0.04% 510
2014
Q2 		– Sell
-1,812
Closed -$463K – 1688
2014
Q1 		$463K Buy
+1,812
New +$554K 0.01% 987
2013
Q3 		– Sell
-2,024
Closed -$359K – 1763
2013
Q2 		$359K Buy
+2,024
New +$287K 0.01% 1201

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PDT Partners's LUMO Position: Q4 2017 in Review

PDT Partners sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2017, closing a stake of 38,887 shares — an estimated $3.56M sold.

PDT Partners first reported a position in LUMO in Q2 2013 and held it in 11 quarters. The position peaked at $3.56M in Q3 2017. 130 funds tracked by Wall St. Rank hold LUMO as of Q4 2017.

  • PDT Partners reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • PDT Partners sold 38,887 Lumos Pharma, Inc. Common Stock shares in Q4 2017, an estimated $3.56M.
  • PDT Partners first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 11 quarters.
  • PDT Partners's Lumos Pharma, Inc. Common Stock position peaked at $3.56M in Q3 2017.
  • 130 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2017.

Based on PDT Partners's 13F filing for Q4 2017, filed 14 Feb 2018.